KCT0004005终止未知
Bortezomib with lenalidomide and dexamethasone combination as induction therapy in transplantation candidate patients with newly diagnosed multiple myeloma: A prospective phase II study by Korean Multiple Myeloma Working Party
试验速览
- 阶段
- 未知
- 状态
- 终止
- 入组人数
- 74
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 64(Year)（—）
- 性别
- All
入选标准
- •(1) Newly diagnosed multiple myeloma
- •(2) Age =19 years old and <65 years old
- •(3) Untreated patients
- •(4) Measurable serum (>1 g/dL) and 24 hours urine (>0.2 g/24 hour) M-protein
- •(5) Eastern Cooperative Oncology Group Performance Status 0-2
- •(6) Adequate hematological counts, kidney, liver, and cardiac function
- •a. ANC > 1.5 x 109/L and platelet count > 75 x 109/L unless due to bone marrow involvement
- •b. Creatinine clearance = 50 mL / min (calculated by Cockcroft-Gault formula)
- •c. ALT, AST = 2 x UNL, Total bilirubin = 2 x UNL
- •d. Cardiac ejection fraction (MUGA scan or echocardiography) = 45%
- •(7) Patients who decided to voluntarily participate in the study and agreed with informed consent
- •(8) Eligible patients with autologous stem cell transplantation
- •(9) Female patients who:
- •a. Are naturally postmenopausal for at least 2 year before enrolment
- •b. Are surgically sterile
- •c. In the case of a pregnant woman, the pregnant woman must agree on the following:
- •i. adhere to the lenalidomide pregnancy prevention risk management program in Appendix 6
- •ii. All women of childbearing potential must agree to have two negative pregnancy test within 10-14 days and 24hrs before commencing lenalidomide and use two reliable methods of contraception simultaneously or practice complete abstinence from any heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting study; 2) while participating in the study; 3) dose interruptions; and 4) for at least 28 days after study treatment discontinuation. The two methods of reliable contraception must include one highly effective method and one additional effective method to prevent pregnancy, not plan on conceiving children during or within 6 months following lenalidomide. (See Appendix E Pregnancy Prevention and Risk Management Program).
- •(10) Male patients, even if surgically sterilized (i.e. status post-vasectomy), who:
- •a. Agree to practice effective barrier contraception during the entire study treatment period and through 28 days after the last dose of study treatment
- •b. Agree to completely abstain from heterosexual intercourse
- •c. Must also adhere to the guidelines of the lenalidomide pregnancy prevention and risk management program
排除标准
- •(1) Primary amyloidosis, Smoldering myeloma, Solitary plasmacytoma, monoclonal gammopathy with undetermined significance (MGUS)
- •(2) Prior chemotherapy for multiple myeloma
- •(3) Secondary malignant tumor within last 5 years. The following are exceptions: properly treated squamous cell and basal cell carcinoma of the skin, carcinoma in situ of the cervix
- •(5) Patients with peripheral neuropathy = Grade 2(NCI-CTCAE version 5)
- •(6) Patients with HIV positive
- •(7) Patients with active hepatitis B or C infection
- •(8) Patients with uncontrolled diabetes
- •(9) Have received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
- •10) Hypersensitivity for bortezomib and its Ingredients
- •11) Hypersensitivity for lenalidomide and its Ingredients
- •12) Hypersensitivity for dexamethasone and its Ingredients
- •13) Patients with acute interstitial lung disease or pericarditis
- •14) Patients with genetic problems such as galactose intolerance, Lapp lactose dehydrogenase deficiency or glucose-galactose uptake disorder
- •15) Patient with live vaccine injected
- •16) Patients with Herpes simplex, herpes zoster, varicella infection
- •17) Infection without effective antimicrobial agent or systemic fungal infection
研究者
相似试验
尚未招募
3 期
A comparison of Bortezomib, Pomalidomide with low-dose Dexamethasone and Bortezomib, Lenalidomide with low-dose dexamethasone for newly-diagnosed multiple myeloma patients- A randomized phase III study.CTRI/2019/07/020397Dr Lalit Kumar
已完成
2 期
Bortezomib, cyclophosphamide plusd dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myelomaJPRN-UMIN000009765Kanagawa Cancer Center30
招募中
2 期
Efficacy of Bortezomib, Lenalidomide and Dexamethasone combination therapy after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma patientsCTRI/2017/06/008741All India Institute of Medical Sciences93
招募中
2 期
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple MyelomaMyelomaNewly DiagnosedHigh RiskNCT03641456Sun Yat-sen University50
已完成
2 期
Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma RelapseMultiple MyelomaACTRN12606000180516Peter MacCallum Cancer Centre100